X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company developing and commercializing therapeutics for rare hematology diseases. Its primary asset, mavorixafor, is an oral small-molecule antagonist of the CXCR4 receptor that promotes the mobilization of mature white blood cells from bone marrow into… From the company’s description.
Over the twelve months to Sep 30, 2026, X4 Pharmaceuticals, Inc reported revenue of $16.96M, down 50.1% from a year earlier, and a net loss of $80.52M. Its operating margin was −474.0%, and operations used $76.10M in cash. In fiscal 2025, it reported revenue of $35.11M, up 1273.2% from fiscal 2024, and a net loss of $79.20M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What X4 Pharmaceuticals, Inc does
In the company’s own words
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company developing and commercializing therapeutics for rare hematology diseases. Its primary asset, mavorixafor, is an oral small-molecule antagonist of the CXCR4 receptor that promotes the mobilization of mature white blood cells from bone marrow into the bloodstream. The company’s approved product, XOLREMDI (mavorixafor), is indicated in the United States for patients aged 12 and older with WHIM syndrome to increase circulating mature neutrophils and lymphocytes. Mavorixafor is also in a global Phase 3 trial for chronic neutropenia, with or without stable granulocyte colony-stimulating factor treatment. X4 makes XOLREMDI available in the United States and works with partners to commercialize or distribute it in international markets, including through Norgine in Europe, Australia and New Zealand. It relies on third-party contractors to manufacture its drug substance and finished product. The company reported $226.6 million in revenue for fiscal 2025. Its website is https://www.x4pharma.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1501697
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns X4 Pharmaceuticals, Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · X4 Pharmaceuticals, Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do X4 Pharmaceuticals, Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of X4 Pharmaceuticals, Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in X4 Pharmaceuticals, Inc's last four quarterly filings that the numbers alone won't show?”